Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

CHECKLIST FOR PRESCRIBERS EMTRICITABINE/TENOFOVIR

Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP) Complete checklist at each visit and file in individual’s medical record.

For Healthcare Professionals

Important safety information for individuals to reduce the risk of getting HIV

This guide is intended for information only and should complement (not replace) the patient information leaflet supplied with your medicine. For a full list of side effects and other important information, please refer to the patient information leaflet provided in the box containing your medicine. Ask your healthcare provider if you have any questions.

For Healthcare Professionals

important safety information for prescribers v2 Tenofovir PrEP

Emtricitabine/ tenofovir disoproxil is indicated in combination with safer sex practices for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and on men and women in heterosexual serodiscordant couples.

For Healthcare Professionals

Reminder card v2 Tenofovir PrEP

You have been prescribed emtricitabine/ tenofovir disoproxil for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. For this medicine to work effectively it is important that you don’t miss doses. The recommended dose is one emtricitabine/ tenofovir disoproxil tablet each day. Take emtricitabine/ tenofovir disoproxil exactly as your doctor has told you.

For Healthcare Professionals

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL:TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

Submission of Risk Minimisation Materials (coordinated by BGMA) to agency – minimising the risks of renal and bone effects for children and adolescents with HIV

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.